Akebia Therapeutics, Inc.

NasdaqCM:AKBA Stock Report

Market Cap: US$399.3m

Akebia Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:AKBA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
29 Feb 24SellUS$9,439Nicole HadasIndividual5,974US$1.58
29 Feb 24SellUS$13,684Michel DahanIndividual8,661US$1.58
29 Feb 24SellUS$73,581John ButlerIndividual46,570US$1.58
29 Feb 24SellUS$11,327Steven BurkeIndividual7,169US$1.58
27 Feb 24SellUS$57,354John ButlerIndividual37,733US$1.52
27 Feb 24SellUS$16,331Michel DahanIndividual10,744US$1.52
01 Feb 24SellUS$40,842Steven BurkeIndividual24,311US$1.68
01 Feb 24SellUS$78,102John ButlerIndividual46,489US$1.68

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AKBA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders5,704,8192.61%
VC/PE Firms14,202,5586.51%
Institutions53,894,62124.7%
General Public144,379,20466.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.8%.

Top Shareholders

Top 25 shareholders own 31.15% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.97%
BlackRock, Inc.
15,197,207US$27.8m30.6%no data
6.51%
Alerce Investment Management L.P.
14,202,558US$26.0m0%33.16%
4.62%
The Vanguard Group, Inc.
10,070,298US$18.4m8.56%no data
2.18%
Geode Capital Management, LLC
4,754,464US$8.7m4.81%no data
1.7%
Renaissance Technologies LLC
3,717,800US$6.8m-5.03%0.01%
1.57%
State Street Global Advisors, Inc.
3,430,527US$6.3m24.9%no data
0.93%
Jacobs Levy Equity Management Inc
2,034,169US$3.7m-2.89%0.01%
0.92%
Muneer Satter
2,002,561US$3.7m0%no data
0.75%
Northern Trust Global Investments
1,635,099US$3.0m274%no data
0.67%
John Butler
1,467,810US$2.7m0%no data
0.61%
Qube Research & Technologies Ltd
1,323,729US$2.4m-24.1%no data
0.5%
Morgan Stanley, Investment Banking and Brokerage Investments
1,088,242US$2.0m42.6%no data
0.48%
Connor, Clark & Lunn Investment Management Ltd.
1,046,691US$1.9m0.06%0.01%
0.4%
Federated Hermes, Inc.
868,021US$1.6m0.32%no data
0.31%
FMR LLC
680,062US$1.2m26.2%no data
0.31%
Michel Dahan
672,092US$1.2m0%no data
0.3%
Nicole Hadas
651,243US$1.2m0%no data
0.26%
Charles Schwab Investment Management, Inc.
568,667US$1.0m-0.4%no data
0.22%
BNY Asset Management
469,708US$859.6k-22.3%no data
0.2%
Goldman Sachs Group, Investment Banking and Securities Investments
433,257US$792.9k63.6%no data
0.19%
Wellington Management Group LLP
404,718US$740.6k0%no data
0.17%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
380,535US$696.4k0%no data
0.16%
Steven Burke
342,840US$627.4k0%no data
0.13%
Barclays PLC Private Banking & Investment Banking Investment
273,085US$499.7k276%no data
0.11%
Bank of America Corporation, Asset Management Arm
248,900US$455.5k17.7%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 17:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akebia Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Jonathan AschoffBrean Capital
Jonathan AschoffB. Riley Wealth